Medicare Pays 22% More For Biosimilar Inflectra Than Reference Biologic

By John Wilkerson / January 19, 2017 at 1:43 PM

Medicare pays 22 percent more for the biosimilar Inflectra than for that of its reference product Remicade, according to congressional Medicare advisers.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.